BBIO4:01 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO4:01 PMBridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updatesbridgebio.com
BBIO7:30 AMBridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ETbridgebio.com
BBIO4:01 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO7:30 AMAcoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CMbridgebio.com
BBIO7:30 AMBridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launchesbridgebio.com
BBIO4:00 PMBridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with AchondroplasiaTrial Results • Phase 3bridgebio.com
BBIO4:31 PMBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)bridgebio.com
BBIO7:30 AMBridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026Presentation / Abstract • Phase 3bridgebio.com
BBIO7:30 AMBridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9bridgebio.com